Affordable Access

Publisher Website

LIGNOCAINE IN THE MANAGEMENT OF ARRHYTHMIAS AFTER ACUTE MYOCARDIAL INFARCTION

Authors
Journal
The Lancet
0140-6736
Publisher
Elsevier
Publication Date
Volume
291
Issue
7537
Identifiers
DOI: 10.1016/s0140-6736(68)90120-7

Abstract

Abstract The value of intravenous lignocaine ('Xylocaine') in the management of arrhythmias after acute myocardial infarction has been assessed. Of twenty-seven patients with frequent ventricular extrasystoles, adequate suppression was achieved in twenty-four using a continuous intravenous infusion of lignocaine 1-2 mg. per minute. Ventricular tachycardia was terminated in eleven patients by a single intravenous injection of 1-2 mg. per kg. body-weight, without resort to D.C. cardioversion. Lignocaine was of little value in the management of supraventricular arrhythmias. Hæmodynamic studies in eight patients have shown no deleterious side-effects after intravenous lignocaine in this dosage. It is suggested that lignocaine is the anti-arrhythmic drug of choice in the management of ventricular arrhythmias after acute myocardial infarction.

There are no comments yet on this publication. Be the first to share your thoughts.